4.8 Review

Microbiome and Anticancer Immunosurveillance

期刊

CELL
卷 165, 期 2, 页码 276-287

出版社

CELL PRESS
DOI: 10.1016/j.cell.2016.03.001

关键词

-

资金

  1. Ligue contre le Cancer (equipe labelisee)
  2. Agence National de la Recherche (ANR)-Projets blancs
  3. ANR
  4. ERA-Net for Research on Rare Diseases
  5. Association pour la recherche sur le cancer (ARC)
  6. Canceropole Ile-de-France
  7. Institut National du Cancer (INCa)
  8. Institut Universitaire de France
  9. Fondation pour la Recherche Medicale (FRM)
  10. European Commission (ArtForce)
  11. European Research Council (ERC)
  12. LeDucq Foundation
  13. LabEx Immuno-Oncology
  14. SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE)
  15. SIRIC Cancer Research and Personalized Medicine (CARPEM)
  16. Paris Alliance of Cancer Research Institutes (PACRI)
  17. Cancer Research Institute (CRI)
  18. Ludwig Institute for Cancer Research (LICR)

向作者/读者索取更多资源

Anticancer immune responses can be considered a desirable form of autoimmunity that may be profoundly shaped by the microbiome. Here, we discuss evidence for the microbiome's influence on anti-tumor immunosurveillance, including those that are indirect and can act at a distance, and we put forward hypotheses regarding mechanisms of how these effects are implemented. These may involve cross-reactivity between microbial and tumor antigens shaping T cell repertoires and/or microbial products stimulating pattern recognition receptors that influence the type and intensity of immune responses. Understanding how the microbiome impacts natural cancer immunosurveillance as well as treatment-induced immune responses will pave the way for more effective therapies and prophylactics.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据